The primary goal in the treatment of
osteoporosis is to prevent skeletal fractures. Modern
antiresorptive drugs reduce the number of fractures in patients with moderate
osteoporosis, but they cannot repair serious damage to bone structure. Both experimental investigations and clinical trials have shown that daily
injections of
parathyroid hormone or its amino-terminal fragment (1-34) increase the number and activity of osteoblasts, and accelerate formation of new bone tissue. In postmenopausal women with severe
osteoporosis, treatment with the amino-terminal fragment of recombinant human
parathyroid hormone, given once a day as a
subcutaneous injection, results in a significant increase in the bone mineral density of the spine and proximal femur, without impairing bone quality. 18-month treatment with PTH decreases the risk of both
compression fractures of the spine and nonvertebral
osteoporotic fractures by more than 50%.
Parathyroid hormone in the recommended dose of 20 g daily has proved to be a safe and effective
drug, stimulating the reconstruction of structurally damaged bone and significantly decreasing fracture risk in patients with severe
osteoporosis.